Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Caron

Showing results (301-310 of 331) with videos related to

Pageof 34
Sort By:
Cancer|February 1, 1994
Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemiaP C Caron, M A Schwartz, M S Co, et al.
Leukemia|February 1, 1995
Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195J G Jurcic, P C Caron, W H Miller, et al.
Thrombosis and Haemostasis|December 30, 1998
A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrateJ Goudemand, J Peynet, H Chambost, et al.
Lupus|July 22, 2017
Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control studyC M Yelnik, G Urbanski, E Drumez, et al.
Lupus|May 7, 2011
Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patientsG Lefèvre, M Lambert, J-L Bacri, et al.
L'Union Medicale Du Canada|December 1, 1978
[Primary hyperparathyroidism: study of 21 cases in the region of Eastern districts]L Frenette, N Kandalaft, B Bénard, et al.
International Journal of Laboratory Hematology|March 21, 2017
Agreement between factor XIII activity and antigen assays in measurement of factor XIII: A French multicenter study of 147 human plasma samplesC Caron, R Meley, V Le Cam Duchez, et al.
Blood|April 1, 1994
A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicityP C Caron, J G Jurcic, A M Scott, et al.
Journal of Thrombosis and Haemostasis : JTH|October 1, 2005
Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methodsJ Goudemand, I Scharrer, E Berntorp, et al.
Transfusion Medicine (Oxford, England)|September 26, 2009
Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag systemM El-Ekiaby, M A Sayed, C Caron, et al.
Pageof 34

Showing results (301-310 of 331) with videos related to

Sort By:
Pageof 34
Cancer|February 1, 1994
Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemiaP C Caron, M A Schwartz, M S Co, et al.
Leukemia|February 1, 1995
Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195J G Jurcic, P C Caron, W H Miller, et al.
Thrombosis and Haemostasis|December 30, 1998
A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrateJ Goudemand, J Peynet, H Chambost, et al.
Lupus|July 22, 2017
Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control studyC M Yelnik, G Urbanski, E Drumez, et al.
Lupus|May 7, 2011
Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patientsG Lefèvre, M Lambert, J-L Bacri, et al.
L'Union Medicale Du Canada|December 1, 1978
[Primary hyperparathyroidism: study of 21 cases in the region of Eastern districts]L Frenette, N Kandalaft, B Bénard, et al.
International Journal of Laboratory Hematology|March 21, 2017
Agreement between factor XIII activity and antigen assays in measurement of factor XIII: A French multicenter study of 147 human plasma samplesC Caron, R Meley, V Le Cam Duchez, et al.
Blood|April 1, 1994
A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicityP C Caron, J G Jurcic, A M Scott, et al.
Journal of Thrombosis and Haemostasis : JTH|October 1, 2005
Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methodsJ Goudemand, I Scharrer, E Berntorp, et al.
Transfusion Medicine (Oxford, England)|September 26, 2009
Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag systemM El-Ekiaby, M A Sayed, C Caron, et al.
Pageof 34